Skip to content
DeeptechNavigator

Insights · tech brief

India's Drug Delivery Systems: From Solubility to Smart Implants

Indian innovators are rethinking how medicines reach their targets—tackling solubility, sustaining release, and building smarter delivery devices.

Published 21 Jul 2026

Momentum
rising
Investment climate
cautious but focused
Regulatory tailwind
emerging

The Problems Being Solved

Many promising drugs never reach their full potential because they simply don't dissolve well enough in the body. In India, innovators are zeroing in on this solubility bottleneck for a wide range of hydrophobic compounds—think telmisartan, curcumin, berberine, and etoricoxib—where poor oral absorption limits efficacy.

Beyond solubility, chronic diseases demand more than a quick-release pill. The need for controlled, sustained release is driving work on systems that stay in the stomach longer, release drugs over days or weeks, or target specific tissues to minimize side effects. Patient convenience is equally critical: swallowing difficulties, the need for rapid onset, and frequent dosing all push for alternatives like oral films, sublingual strips, and transdermal patches.

Underpinning these efforts is a surge in novel carrier systems—polymeric micelles, solid lipid nanoparticles, dendrimers, and nanosponges—that encapsulate, protect, and deliver drugs more intelligently. And at the device end, automated dispensers, microneedle patches, and implantable systems are being designed for precise, long-acting administration, including for conditions like HIV.

How the Field Is Solving It

The technical response is as diverse as the problems. Polymeric micelles and nanoparticles use amphiphilic polymers to trap hydrophobic drugs in a water-friendly shell, dramatically boosting solubility and bioavailability. Solid dispersions and cyclodextrin complexes take a different route—dispersing the drug in a hydrophilic carrier or forming host-guest complexes to speed up dissolution.

Lipid-based systems are another workhorse. Solid lipid nanoparticles, liposomes, and ethosomes not only improve encapsulation but also enable controlled release and deeper skin penetration for topical therapies. For drugs that need to linger in the stomach or adhere to mucosal surfaces, floating and mucoadhesive formulations extend residence time and enhance absorption.

On the device side, microneedle patches with core-shell structures painlessly pierce the skin for transdermal delivery, while implantable systems promise months-long release for chronic conditions. Automated delivery devices—featuring robotic arms, reservoir supports, and aseptic transfer—are raising the bar for safety and precision in clinical and home settings.

Where the Market Is Heading

Globally, the drug delivery systems market is substantial and steadily growing. Fortune Business Insights estimates the market at roughly USD 48 billion in 2025, with a mid-single-digit annual growth rate through 2034. The broader advanced drug delivery space is even larger, while the electronic delivery segment alone was valued in the low tens of billions in 2024, according to Grand View Research.

Several trends are reshaping the field. Self-administration and wearable devices—insulin pumps, auto-injectors—are gaining ground for chronic disease management. AI and machine learning are being woven into formulation design to personalize release profiles, as noted by MedTech Outlook. Meanwhile, nanocarrier platforms originally developed for small molecules are now being adapted for mRNA and siRNA delivery, a shift highlighted by Mordor Intelligence. Smart, stimuli-responsive implants that release drugs based on physiological cues are moving from concept to early reality.

In India, the picture is one of focused momentum amid a cautious funding environment. Pharma startups are actively pursuing novel formulations and delivery tech, but overall investment has tightened to the low tens of millions, as reported by Express Pharma. On the regulatory front, proposed reforms could halve clinical trial approval timelines, a move that RAPS suggests may significantly accelerate development of new delivery systems in the country.

The White Space

While small-molecule delivery is advancing rapidly, the delivery of biologics, peptides, and nucleic acids remains a wide-open frontier. Most current Indian innovation clusters around conventional hydrophobic drugs; macromolecule delivery—requiring protection from degradation, targeted intracellular delivery, and sophisticated release kinetics—is only beginning to attract attention.

Smart, stimuli-responsive systems that automate dosing based on real-time physiological feedback are still nascent, presenting an opportunity to combine India's strengths in low-cost engineering with advanced materials. The growing push toward self-administration opens doors for user-friendly, affordable devices tailored to Indian healthcare settings. And with regulatory pathways potentially becoming faster, the window is widening for clinical validation of novel carriers and implantables. The next wave of innovation will likely come from bridging these gaps—making biologics delivery as routine as oral tablets, and embedding intelligence into the delivery system itself.

Explore the Innovators

The specific inventors, patents, and companies driving these advances in India—from nanosponge-based formulations to automated dispensing robots—can be explored in depth on Deeptech Navigator. The platform maps the people and ideas behind the patents, offering a direct view into where the country's drug delivery innovation is heading.

Knowledge graph

How the technologies, companies and players in this briefing connect.

problem

Poor solubility of hydrophobic drugsNeed for controlled & sustained releaseTargeted delivery to reduce side effectsPatient compliance & ease of administrationDelivery of biologics & macromolecules

approach

Polymeric micelles & nanoparticlesSolid dispersions & complexesLipid-based carriers (SLNs, liposomes)Mucoadhesive & gastro-retentive systemsMicroneedle & implant technologiesAutomated delivery devices

technology

Oral films & sublingual stripsTransdermal patchesNanocarriers for mRNA/siRNASmart stimuli-responsive implantsAI-driven formulation design

In our data

Sectors

Health & Life Sciences

Technologies

drug delivery systems

Sources

This briefing is AI-generated from Deeptech Navigator's patent and startup data and lightly reviewed before publishing. Treat it as a starting point, not professional advice - figures are directional, so verify before relying on any number. The platform takes no responsibility for decisions made on it.

Related briefings

funding brief

The RDI Fund's 19 New Managers Get ₹7,131 Crore. The Companies They Back Raised ₹2,823 Crore Last Year.

India's RDI Fund has approved its first 19 private and research-body fund managers. In our data they are linked to 276 deep-tech companies, 1% of our list, which closed ₹2,823 crore of named private equity rounds in the past year. The commitment equals 33% of a year of such rounds across all deep-tech companies on our list.

funding brief

Space Took a Quarter of the RDI Fund's First Approvals. AI Took ₹3 Crore.

We set TDB's first 22 RDI approvals against where India's deep-tech companies and patent filings are. Space took a quarter of the money from 2% of the companies on our list. AI took 0.1%. Karnataka sent nearly a third of the proposals; Gujarat sent four.

funding brief

Missions Outspend Investors 115 to 1 in Chips. In Space, Investors Lead 7 to 1.

We set ten government missions and funds against the private rounds on our record in the same sectors. In chips, quantum, critical minerals and green hydrogen, the state has committed more than every private round the sector's startups have on our record. In space, robotics, defence, health and mobility, investors have put in more. AI is close to level.

funding brief

The RDI Fund Pays Half. How Many Indian Deeptech Companies Can Raise the Other Half?

The ₹1 lakh crore RDI Fund will finance no more than half of a project; the company must find the rest. The first 22 approvals needed a median ₹101 crore each from their own or private sources. In the past year, 47 deep-tech companies on our list closed a private round of ₹100 crore or more.

funding brief

The RDI Fund's First 22 Companies: ₹2,192 Crore Approved, ₹376 Crore Paid

The Technology Development Board, the first manager to lend from India's ₹1 lakh crore Research, Development and Innovation Fund, has approved 22 companies for ₹2,192 crore against projects worth ₹4,744 crore. By 30 September it had paid ten of them ₹375.69 crore. Here is the full list, what each is building, and what our data says about them.

tech brief

Indian Deeptech Reaches Series B at 7%. Its Space Companies Do It at 19%.

A reader asked whether our Series B figure was a real graduation rate. It was not, so we recomputed it. The deeptech-versus-everything-else gap did not survive the recount. The gap inside deeptech did, and it runs from zero to nineteen percent.

Get in touch

Have a question on this - or want it researched for you?

Send a note: feedback on this briefing, a data question, or a scoped custom study on your specific market, geography or patent question. No account or card needed - we reply by email, usually within 1 business day.

No card charged, no account needed - we reply by email.